Colorectal cancer is the second leading cause of cancer deaths worldwide and the third most diagnosed cancer, affecting over a million people annually. The problem worsens if the tumor is metastatic, meaning it moves from the original organ to other parts of the body. In this scenario, the five-year survival rate drops from 70–90% to just 10%.
New biomarker shows potential to evaluate treatment response for metastatic colorectal cancer retrieved 15 July 2024 from https://medicalxpress.com/news/2024-07-biomarker-potential-treatment-response-metastatic.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.Feb 6, 20245 hours ago Use this form if you have come across a typo, inaccuracy or would like to send an edit request for the content on this page. For general inquiries, please use ourThank you for taking time to provide your feedback to the editors.
Your feedback is important to us. However, we do not guarantee individual replies due to the high volume of messages.to let the recipient know who sent the email. Neither your address nor the recipient's address will be used for any other purpose. The information you enter will appear in your e-mail message and is not retained by Medical Xpress in any form.Get weekly and/or daily updates delivered to your inbox.
Medicine Research Health Research News Health Research Health Science Medicine Science
United Kingdom Latest News, United Kingdom Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Research identifies possible new pathway to treatment of colorectal cancerResearch led by Irving Coy Allen in the Virginia-Maryland College of Veterinary Medicine has unlocked a pathway to possible future treatments for colorectal cancer in humans.
Read more »
Potential new target for colorectal cancer treatmentResearchers have identified a protein called PFDN6 that may play a role in the development and spread of colorectal cancer (CRC). The study, published in [journal name], found that PFDN6 levels are increased in CRC patients and contribute to tumor growth.
Read more »
PFDN6 protein could be a new target for colorectal cancer treatmentResearchers have identified a protein called PFDN6 that may play a role in the development and spread of colorectal cancer (CRC).
Read more »
New name, new uniform and new principal at Telford secondary schoolA Telford secondary school has announced the start of an ambitious new era – with a new name, new uniform, and a new principal.
Read more »
Exploring the intricate signaling pathways in colorectal cancer: Implications for targeted therapiesColorectal cancer (CRC) is a leading cause of cancer-related deaths worldwide. The complexity of its pathogenesis, involving genetic mutations, dysregulated signaling pathways, and compromised immune surveillance, presents significant challenges for effective treatment.
Read more »
The current state of immunotherapy in colorectal cancerColorectal cancer (CRC) is a major health concern worldwide, characterized by high incidence and mortality rates. Despite advances in treatment, metastatic CRC (mCRC) remains particularly challenging.
Read more »